JP2020505054A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505054A5 JP2020505054A5 JP2019542388A JP2019542388A JP2020505054A5 JP 2020505054 A5 JP2020505054 A5 JP 2020505054A5 JP 2019542388 A JP2019542388 A JP 2019542388A JP 2019542388 A JP2019542388 A JP 2019542388A JP 2020505054 A5 JP2020505054 A5 JP 2020505054A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- polypeptide
- acid substitution
- polypeptide according
- kabat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims 48
- 125000003275 alpha amino acid group Chemical group 0.000 claims 35
- 235000001014 amino acid Nutrition 0.000 claims 32
- 238000006467 substitution reaction Methods 0.000 claims 32
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000004475 Arginine Substances 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- 239000004472 Lysine Substances 0.000 claims 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 8
- 235000004279 alanine Nutrition 0.000 claims 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims 4
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 208000001528 Coronaviridae Infections Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims 2
- 239000001825 Polyoxyethene (8) stearate Substances 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000004337 magnesium citrate Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 108700012439 CA9 Proteins 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022211496A JP7606501B2 (ja) | 2017-02-06 | 2022-12-28 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
| JP2024218361A JP2025028191A (ja) | 2017-02-06 | 2024-12-13 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455245P | 2017-02-06 | 2017-02-06 | |
| US62/455,245 | 2017-02-06 | ||
| PCT/US2018/017027 WO2018145075A1 (en) | 2017-02-06 | 2018-02-06 | Compositions and methods for augmenting antibody mediated receptor signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211496A Division JP7606501B2 (ja) | 2017-02-06 | 2022-12-28 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505054A JP2020505054A (ja) | 2020-02-20 |
| JP2020505054A5 true JP2020505054A5 (OSRAM) | 2021-03-18 |
| JP7231549B2 JP7231549B2 (ja) | 2023-03-01 |
Family
ID=63040120
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542388A Active JP7231549B2 (ja) | 2017-02-06 | 2018-02-06 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
| JP2022211496A Active JP7606501B2 (ja) | 2017-02-06 | 2022-12-28 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
| JP2024218361A Pending JP2025028191A (ja) | 2017-02-06 | 2024-12-13 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211496A Active JP7606501B2 (ja) | 2017-02-06 | 2022-12-28 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
| JP2024218361A Pending JP2025028191A (ja) | 2017-02-06 | 2024-12-13 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20220213206A1 (OSRAM) |
| EP (1) | EP3576793A4 (OSRAM) |
| JP (3) | JP7231549B2 (OSRAM) |
| CN (1) | CN110520158A (OSRAM) |
| AU (2) | AU2018215673B2 (OSRAM) |
| CA (1) | CA3049689A1 (OSRAM) |
| WO (1) | WO2018145075A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102534568B1 (ko) * | 2016-07-22 | 2023-05-18 | 다나-파버 캔서 인스티튜트 인크. | 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr) 항체 및 이의 이용 방법 |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| MX2021000532A (es) | 2018-07-19 | 2021-04-12 | Regeneron Pharma | Receptores antigénicos quiméricos con especificidad para bcma y usos de estos. |
| RU2734432C1 (ru) * | 2019-04-23 | 2020-10-16 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с GITR |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| CN120309734A (zh) | 2021-01-13 | 2025-07-15 | 威特拉公司 | 人源化补体5a受体1抗体和其使用方法 |
| US20240239905A1 (en) * | 2021-05-13 | 2024-07-18 | Arizona Board Of Regents On Behalf Of Arizona State University | A plant produced anti-egfr mabs with specific glycosylation to improve the efficacy against cancer |
| CN115873126A (zh) * | 2021-11-26 | 2023-03-31 | 深圳科兴药业有限公司 | 人生长激素融合蛋白及其制备和用途 |
| AU2023324667A1 (en) | 2022-08-15 | 2025-02-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
| WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997031020A1 (en) * | 1996-02-22 | 1997-08-28 | The General Hospital Corporation | METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR RESPONSE TO TGF-β LIGANDS |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| AU2015200990B2 (en) * | 2009-03-20 | 2016-07-21 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Optimized Fc variants |
| US11180572B2 (en) * | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
| AU2013372331A1 (en) * | 2013-01-10 | 2015-07-23 | Genmab B.V. | Human IgG1 Fc region variants and uses thereof |
| US9963513B2 (en) * | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
| DK3189081T3 (da) * | 2014-09-05 | 2020-05-04 | Janssen Pharmaceutica Nv | Cd123-bindende midler og anvendelser deraf |
| EP3215528B1 (en) * | 2014-11-06 | 2019-08-07 | F.Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding and methods of use |
| WO2016139365A1 (en) * | 2015-03-05 | 2016-09-09 | Ucb Biopharma Sprl | Polymeric fc proteins and methods of screening to alter their functional characteristics |
| HK1249532A1 (zh) * | 2015-04-07 | 2018-11-02 | F. Hoffmann-La Roche Ag | 具有激动剂活性的抗原结合复合体及使用方法 |
| CN110214152B (zh) * | 2016-10-14 | 2025-06-13 | 丹娜法伯癌症研究所公司 | 模块化四聚体双特异性抗体平台 |
| JP7277363B2 (ja) * | 2016-11-01 | 2023-05-18 | ジェンマブ ビー．ブイ． | ポリペプチド変異体およびその使用 |
-
2018
- 2018-02-06 CA CA3049689A patent/CA3049689A1/en not_active Abandoned
- 2018-02-06 JP JP2019542388A patent/JP7231549B2/ja active Active
- 2018-02-06 CN CN201880010285.3A patent/CN110520158A/zh active Pending
- 2018-02-06 AU AU2018215673A patent/AU2018215673B2/en active Active
- 2018-02-06 US US16/483,738 patent/US20220213206A1/en not_active Abandoned
- 2018-02-06 WO PCT/US2018/017027 patent/WO2018145075A1/en not_active Ceased
- 2018-02-06 EP EP18748152.8A patent/EP3576793A4/en active Pending
-
2022
- 2022-12-28 JP JP2022211496A patent/JP7606501B2/ja active Active
-
2023
- 2023-12-04 US US18/528,382 patent/US20240336694A1/en active Pending
-
2024
- 2024-12-13 JP JP2024218361A patent/JP2025028191A/ja active Pending
-
2025
- 2025-04-22 AU AU2025202811A patent/AU2025202811A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023036899A5 (OSRAM) | ||
| JP7279142B2 (ja) | 免疫調節剤 | |
| JP7809372B2 (ja) | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 | |
| AU2019301204B2 (en) | Antibody molecules that bind PD-L1 and CD137 | |
| JP7148539B2 (ja) | 免疫抱合体 | |
| JP7603205B2 (ja) | 抗体分子 | |
| JP2024045143A (ja) | 抗ｐｄ－１抗体と突然変異ｉｌ－２とまたはｉｌ－１５とのイムノコンジュゲート | |
| JP6731403B2 (ja) | 免疫応答およびがん治療の増強に使用するための組成物および方法 | |
| JP2026063140A (ja) | 二機能性抗ｐｄ－１／ｉｌ－７分子 | |
| CA3095310A1 (en) | Bi-functional proteins and construction thereof | |
| FI3606955T3 (fi) | Pd1:een ja lag3:een spesifisesti sitoutuvia bispesifisiä vasta-aineita | |
| JP2019529373A5 (ja) | 抗Ｔｉｍ−３抗体 | |
| KR20190070977A (ko) | 폴리펩티드 변이체 및 그의 용도 | |
| CN113302205A (zh) | 激动性肿瘤坏死因子受体超家族多肽 | |
| JP2015120706A5 (OSRAM) | ||
| CN113574067A (zh) | 双功能抗PD-1/SIRPα分子 | |
| CN115297885A (zh) | 包含基于IL-15/IL-15Rα的异二聚体蛋白质复合物的免疫细胞因子 | |
| CA3109346A1 (en) | Combination therapies comprising sirp alpha-based chimeric proteins | |
| AU2019264217A1 (en) | Antibody variant combinations and uses thereof | |
| CA3118892A1 (en) | Modulation of dendritic cell lineages | |
| EP3743440A1 (en) | Polypeptide variants and uses thereof | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| AU2022211410A1 (en) | Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2 | |
| JP2023554097A5 (OSRAM) | ||
| KR20230027267A (ko) | 항-pd-1 항체 및 융합 단백질 |